Study uncovers proteomic signatures in blood plasma and cervicovaginal fluid that could lead to non-invasive detection methods for endometrial cancer, demonstrating significant potential for early diagnosis and improved patient outcomes.
Madrigal raises $500M for NASH drug launch, discloses cyberattack
Madrigal Pharmaceuticals expects to raise $500 million from a stock and warrants sale, which it plans to use to prepare for the launch of resmetirom